

Amendments to the Claims:

1-60. (Canceled)

61. (Currently amended) A method for inducing an immune response to a flaviviral antigen in a human subject comprising delivering a vaccine expressing the flaviviral antigen to a subject's skin using a device that targets the intradermal compartment of the subject's skin, wherein the device comprises at least one hollow microneedle that delivers the vaccine to the subject's skin to a depth of between 0.025 mm and 2.0 mm.

62-63. (Canceled)

64. (Currently amended) A kit for use in inducing an immune response to a flaviviral antigen in a subject, said kit comprising:

(a) a vaccine expressing the flaviviral antigen; and

(b) a device that targets the intradermal compartment of the subject's skin,
wherein the device comprises:

(1) at least one microneedle, wherein the microneedle is supported by a hub portion and has a forward tip that extends away from the hub portion; and

(2) a limiter portion that surrounds the microneedle and extends away from the hub portion toward the forward tip of the microneedle, wherein the limiter portion comprises a flat skin engaging surface that extends in a plane perpendicular to an axis of the microneedle, the forward tip of the microneedle extending beyond the skin engaging surface at a distance of between 0.5 mm and 2.0 mm.

65. (Canceled)

66. (Previously presented) The method of claim 61, wherein the vaccine is a chimeric Japanese Encephalitis vaccine.

67. (Previously presented) The method of claim 66, wherein the chimeric Japanese Encephalitis vaccine is JE SA14-14-2.

68. (Previously presented) The kit of claim 64, wherein the vaccine is a chimeric Japanese Encephalitis vaccine.

69. (Currently amended) The kit of claim 68 ~~65~~, wherein the chimeric Japanese Encephalitis vaccine is JE SA14-14-2.